INTRODUCTION

81
Small for gestational age (SGA) at birth indicates impaired fetal growth due to a heterogeneous range of 82 intra-uterine conditions or in some infants by innate genetic defects. Around 10% of SGA children do not 83 show spontaneous catch-up growth during the early postnatal years and they are also short as adults if not 84 treated with growth hormone (GH). Most short SGA children have sufficient GH secretion and show 85 generally good responses to GH treatment, although there is considerable variation between patients.
86
Prediction models of the response to GH therapy in short SGA children have been generated in order to 87 individually tailor treatment, to improve efficacy and safety, and to improve the cost-benefit ratio(1). The 
90
We and others reported that the growth response to GH therapy in short SGA children is associated with 91 baseline insulin sensitivity and IGF-I levels(2, 3). Children with the highest baseline IGF-I levels had lower 92 insulin sensitivity, lower height velocity and IGF-I responses after 1-year after GH therapy(3). Insulin 93 secretion is diminished in SGA children and this has been proposed as a possible factor in the failure to 94 catch-up in some infants(4). Furthermore, growth and IGF-I responses to first year GH treatment were 95 related to insulin secretion in the NESGAS study(3). We hypothesised that genetic variation in insulin 96 sensitivity or insulin secretion would be associated with inter-individual variation in responses to GH in short Study assessments:
108
Standing height was measured on a wall-mounted stadiometer and weight by electronic scales by staff. All 109 children underwent a fasting blood sample and a short intravenous glucose tolerance test (IVGTT) at 110 baseline and at year 1(3).
111
Plasma insulin and C-peptide concentrations were measured centrally by a DELFIA-assay (Perkin Elmer   112 Life Sciences, Turku, Finland). Interassay coefficients of variation (CV) were below 4% for both insulin and 113 C-peptide. Serum IGF-I and IGFBP-3 concentrations were determined centrally using an Immulite 2000-114 assay (Diagnostic Products Corporation, LA, USA) with standards calibrated towards the WHO NIBSC IRR 115 87/518. Limit of detection (LOD) and CV was 20ng/ml and 5.93% respectively for IGF-I and 500ng/ml and 116 5.23 % respectively for IGFBP-3. IGF-I and IGFBP-3 SDS were calculated from our reference data (5, 6).
117
Plasma glucose and HbA1c were measured locally.
118
Genotyping information
119
The cohort was genotyped using the Metabochip, a custom Illumina iSelect genotyping array that assays 120 nearly 200,000 single nucleotide polymorphisms (SNPs) chosen based on GWAS meta-analyses (7).
121
In each individual, combined multi-allele scores were generated comprising SNPs for insulin sensitivity (GS-122 InSens) or insulin secretion (GS-InSec), as recently described(8). The GS-InSens was calculated as a count 123 of the insulin sensitivity-increasing alleles at 10 variants (Supplementary Table 2a 
170
However, the GS-InSens was unrelated to HOMA-S or the disposition index at baseline and after 1 year of 171 therapy (Table 2) . Table 3 Associations to measures of growth and metabolism for Insulin Sensitivity multi-allele score (GSInSens) *corrected for age, sex and BMI, **corrected for age, sex and mid-parental height
The regression coefficient (B) are the inverse of the Insulin resistance score (IR score) described by Scott et al. An increase in multi-allele score reflects a decrease in insulin sensitivity. 
Measure of growth and metabolism
